Get the Stockscreener App
1.6199
1.22%
-0.0301
Geovax Labs Inc stock is traded at $1.6199, with a volume of 1.24M.
It is down -1.22% in the last 24 hours and down -4.68% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
See More
Previous Close:
$1.65
Open:
$1.7
24h Volume:
1.24M
Relative Volume:
1.93
Market Cap:
$16.98M
Revenue:
$356.60K
Net Income/Loss:
$-24.32M
P/E Ratio:
-0.1753
EPS:
-9.24
Net Cash Flow:
$-27.24M
1W Performance:
-10.93%
1M Performance:
-4.68%
6M Performance:
-42.61%
1Y Performance:
-22.75%
1-Day Range:
$1.59
$1.84
1-Week Range:
$1.53
$1.885
52-Week Range:
$1.0901
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1900 LAKE PARK DRIVE, SMYRNA
Compare GOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.62 | 16.98M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
504.15 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.88 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.19 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.30 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.23 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK - Yahoo Finance
GeoVax CEO to Present at 37th Annual Roth Conference, Highlighting COVID-19 Vaccine and Cancer Therapy Research - citybuzz -
GeoVax to Present at the 37th Annual Roth Conference - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 35.5% in February - Defense World
News - Financial Content
Geovax Labs Inc (NASDAQ: GOVX) Could Fell Another -164.9% - Stocks Register
GeoVax Highlights the Critical Role of MVA-Based Vaccines in U.S. Biodefense Strategy - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Response to WHO's Third Declaration of Mpox as a Public Health Emergency of International Concern - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Thursday - Defense World
GeoVax Labs Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
GeoVax Highlights the Role of MVA-Based Vaccines in Advancing Public Health Preparedness - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Rating of “Buy” from Analysts - Defense World
GeoVax Pledges Continued Support for Vaccine Innovation, Transparency, and Public Health - Yahoo Finance
GeoVax shareholders approve warrant exercises - MSN
GeoVax to Highlight Mpox Vaccine Development at Emerging Growth Conference - citybuzz -
GeoVax to Present at the Emerging Growth Conference on February 19, 2025 - Yahoo Finance
GeoVax to Present at the Emerging Growth Conference on February 19, 2025 | News | decaturdailydemocrat.com - Financial Content
GeoVax Congratulates Dr. Valerie Montgomery Rice on Receiving the 2025 Healthcare Champions Lifetime Achievement Award - Yahoo Finance
Was Geovax Labs Inc (GOVX)’s session last reading good? - US Post News
GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs - Financial Content
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - citybuzz -
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Labs Stockholders Approve Warrant Exercise Proposals - Defense World
GeoVax shareholders approve warrant exercises By Investing.com - Investing.com Australia
D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial - Yahoo Finance
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now - GlobeNewswire Inc.
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 - Yahoo Finance
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 - Yahoo Finance
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025 - Yahoo Finance
Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GeoVax adjourns Special Meeting due to low quorum - Investing.com
GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN
3 Penny Stocks Ready to Break Out in 2025 - sharewise
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):